摘要
目的:探究贝利尤单抗在系统性红斑狼疮中的疗效及对淋巴细胞体积、电导、光散射(VCS)参数的影响。方法:选取2020年1月-2021年9月福建医科大学附属第二医院收治的80例系统性红斑狼疮患者,按照随机数字表法将其分为对照组和观察组,每组40例。对照组进行常规系统性红斑狼疮治疗,观察组则在对照组的基础上加用贝利尤单抗进行治疗。比较两组的系统性红斑狼疮治疗总有效率、治疗前后的系统性红斑狼疮疾病活动指数(SLEDAI评分)、免疫指标(补体C3、C4)及淋巴细胞VCS参数[淋巴细胞百分率(LY%)、淋巴细胞电导率(LYC)、淋巴细胞激光散射强度(LYS)及淋巴细胞体积(LYV)]。结果:观察组总有效率高于对照组,差异有统计学意义(P<0.05)。治疗前,两组SLEDAI评分、免疫指标及淋巴细胞VCS参数比较,差异均无统计学意义(P>0.05);治疗12、24周,观察组SLEDAI评分、免疫指标均优于对照组,LY%及LYC均高于对照组,LYS及LYV均低于对照组(P<0.05)。结论:贝利尤单抗在系统性红斑狼疮中的疗效较好,且可显著改善患者的免疫及淋巴细胞VCS参数,因此在系统性红斑狼疮患者中的应用价值较高。
Objective:To investigate the effect of Belimumab in the treatment of patients with systemic lupus erythematosus and its influence on lymphocyte volume,conductivity,light scatter(VCS)parameters.Method:A total of 80 patients with systemic lupus erythematosus admitted to Fujian Medical University,2nd Affiliated Hospital from January 2020 to September 2021 were selected,they were divided into control group and observation group according to the random number table method,with 40 cases in each group.The control group were treated with routine treatment for systemic lupus erythematosus,the observation group were treated with Belimumab on the basis of control group.Then the total effective rates for systemic lupus erythematosus,the systemic lupus erythematosus disease activity index(SLEDAI scores),immune indexes(complement C3 and C4)and lymphocyte VCS parameters[lymphocyte percentage(LY%),lymphocyte conductivity(LYC),lymphocyte scatter(LYS)and lymphocyte volume(LYV)]of two groups were compared.Result:The total effective rate of the observation group was higher than that of the control group,the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in SLEDAI scores,immune indexes and lymphocyte VCS parameters between the two groups(P>0.05);after 12 and 24 weeks of treatment,SLEDAI scores and immune index of observation group were better than those of control group,LY%and LYC were higher than those of control group,LYS and LYV were lower than those of control group(P<0.05).Conclusion:The effect of Belimumab in the treatment of patients with systemic lupus erythematosus is better,and it can significantly improve the immune and lymphocyte VCS parameters,so its application value in the patients with systemic lupus erythematosus is higher.
作者
唐鹏芳
TANG Pengfang.(Fujian Medical University,2nd Affiliated Hospital,Quanzhou 362000,China)
出处
《中国医学创新》
CAS
2023年第11期10-13,共4页
Medical Innovation of China
